阅读说明：本技术 环形rna在系统性红斑狼疮制备治疗药物中的应用 (Application of circular RNA in preparation of therapeutic drugs for systemic lupus erythematosus ) 是由 陈玲玲 杨力 刘楚霄 李响 南芳 于 2019-12-10 设计创作，主要内容包括：本发明提供了具有长度是16bp-33bp的不完整双链结构的环形RNA和/或具有长度是16bp-33bp的不完整双链结构的环形RNA在制备系统性红斑狼疮治疗药物中的应用。(The invention provides application of circular RNA with an incomplete double-chain structure with the length of 16bp-33bp and/or circular RNA with an incomplete double-chain structure with the length of 16bp-33bp in preparation of systemic lupus erythematosus treatment medicines.)

Use of circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp and/or a promoter of circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp in the preparation of a therapeutic agent for systemic lupus erythematosus.

The use of claim 1, further comprising one or more of the following features:

1) the circular RNA having an incomplete double-stranded structure with a length of 16bp-33bp is selected from one or more of circARID1B, circCAMSAP1, circCCNB1, circCNN2, circDHX34, circEPHB4, circEZH2, circFCHO2, circFGFR1, circFKBP8, circKIAA0368, circMBOAT2, circPIP5K1C, circPOLR2 LR2A, circSNPPP 1 PPP1CB, circPROSC, circPTK2, circPVT1, circRELL1, circSDHAF2, circSLC22A23, circSNHG4, circCD, circEM 181, circEMC 1, and circVAC;

2) the circular RNA promoter having an incomplete double-stranded structure of 16bp-33bp in length is selected from one or more of a circARID1B promoter, a circCAMSAP1 promoter, a circCCNB1 promoter, a circCNN2 promoter, a circDHX34 promoter, a circEPHB4 promoter, a circEZH2 promoter, a circFCHO2 promoter, a circFGFR1 promoter, a circFKBP8 promoter, a circKIAA0368 promoter, a circMBOAT2 promoter, a circPIP5K1C promoter, a circPOLR2A promoter, a circPPP1CB promoter, a circPROSC promoter, a circPTK2 promoter, a circPVT1 promoter, a circRELL1 promoter, a circSDHAF2 promoter, a circSLC22A23 promoter, a circSNPB 4 promoter, a circPECS promoter, a CIRCEM 181D promoter, a TMTMTMHG promoter, a promoter, and a TMVAHG 1 promoter.

The use of claim 1, wherein the systemic lupus erythematosus treatment drug has at least one of the following utilities: (1) reducing PKR phosphorylation in monocytes of a patient with systemic lupus erythematosus; (2) the expression level of cell factor IFN-beta and systemic lupus erythematosus diagnosis gene MX-1, LY-6E and IFIT3 in mononuclear cells and immune cell T cells of systemic lupus erythematosus patients is reduced.

The use according to claim 1, wherein the promoter of a circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp is a substance that increases the level of a circular RNA having an incomplete double-stranded structure with a length of 16bp to 33 bp.

The use according to claim 4, characterized in that the level of circular RNA having a incomplete double-stranded structure with a length of 16bp-33bp is increased by means of over-expressing circular RNA having a incomplete double-stranded structure with a length of 16bp-33 bp.

The use according to claim 1, wherein the promoter for the circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp and/or the circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp is the only active ingredient or one of the active ingredients of the therapeutic agent for systemic lupus erythematosus.

A systemic lupus erythematosus therapeutic drug comprises an effective dose of a promoter for circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp and/or circular RNA having an incomplete double-stranded structure with a length of 16bp to 33 bp.

The therapeutic agent for systemic lupus erythematosus of claim 7 further comprising one or more of the following characteristics:

1) the circular RNA having an incomplete double-stranded structure with a length of 16bp-33bp is selected from one or more of circARID1B, circCAMSAP1, circCCNB1, circCNN2, circDHX34, circEPHB4, circEZH2, circFCHO2, circFGFR1, circFKBP8, circKIAA0368, circMBOAT2, circPIP5K1C, circPOLR2 LR2A, circSNPPP 1 PPP1CB, circPROSC, circPTK2, circPVT1, circRELL1, circSDHAF2, circSLC22A23, circSNHG4, circCD, circEM 181, circEMC 1, and circVAC;

2) the circular RNA promoter having an incomplete double-stranded structure of 16bp-33bp in length is selected from one or more of a circARID1B promoter, a circCAMSAP1 promoter, a circCCNB1 promoter, a circCNN2 promoter, a circDHX34 promoter, a circEPHB4 promoter, a circEZH2 promoter, a circFCHO2 promoter, a circFGFR1 promoter, a circFKBP8 promoter, a circKIAA0368 promoter, a circMBOAT2 promoter, a circPIP5K1C promoter, a circPOLR2A promoter, a circPPP1CB promoter, a circPROSC promoter, a circPTK2 promoter, a circPVT1 promoter, a circRELL1 promoter, a circSDHAF2 promoter, a circSLC22A23 promoter, a circSNPB 4 promoter, a circPECS promoter, a CIRCEM 181D promoter, a TMTMTMHG promoter, a promoter, and a TMVAHG 1 promoter.

A systemic lupus erythematosus therapeutic drug combination comprises effective dose of circular RNA with a length of 16bp-33bp incomplete double-chain structure and/or promoter of circular RNA with a length of 16bp-33bp incomplete double-chain structure, and at least one other systemic lupus erythematosus therapeutic drug.

Use of a promoter for a circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp and/or a circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp for the preparation of a medicament having any one or more of the following effects: (1) reducing PKR phosphorylation in monocytes of a patient with systemic lupus erythematosus; (2) the expression level of cell factor IFN-beta and systemic lupus erythematosus diagnosis gene MX-1, LY-6E and IFIT3 in mononuclear cells (PBMC) and immune cell T cells of a systemic lupus erythematosus patient is reduced.

Use of circular RNA with incomplete double-stranded structure with length of 16bp-33bp in preparation or screening of systemic lupus erythematosus treatment drugs.

Use of circular RNA having an incomplete double-stranded structure with a length of 16bp to 33bp for preparing or screening a systemic lupus erythematosus detection reagent.

[ correcting 25.12.2019 according to rule 91 ] use of a reagent for specifically recognizing circular RNA with an incomplete double-stranded structure with the length of 16bp-33bp in preparation of a systemic lupus erythematosus detection kit.

A systemic lupus erythematosus detection kit at least comprises a reagent for specifically recognizing a circular RNA with a length of 16bp-33bp of an incomplete double-stranded structure.